These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22098406)

  • 21. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma.
    Mylam KJ; El-Galaly TC; Hutchings M; Brown P; Himmelstrup B; Gerke O; Gillstrøm D; Sillesen IB; Munksgaard L; Pedersen BB; Christiansen I; Jensen P; Nielsen AL; Pedersen LM
    Leuk Lymphoma; 2014 Jul; 55(7):1563-9. PubMed ID: 24144339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of routine CT scans in the follow-up of diffuse large B-cell lymphomas.
    Mascaró-Pol M; Díez-Feijoo R; Rodriguez-Sevilla JJ; Fernández-Rodriguez C; García-Pallarols F; Flores S; Vazquez I; Rodriguez-Lopez S; Roman D; Gimeno E; Colomo L; Maiques J; Sánchez-González B; Salar A
    Hematology; 2021 Dec; 26(1):709-715. PubMed ID: 34547987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
    Cox MC; Ambrogi V; Lanni V; Cavalieri E; Pelliccia S; Scopinaro F; Monarca B; Marchetti P; Spiriti MA
    Leuk Lymphoma; 2012 Feb; 53(2):263-9. PubMed ID: 21846184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
    Qiao W; Zhao J; Xing Y; Wang C; Wang T
    Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
    Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
    Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
    Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
    Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
    Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
    Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.
    Pingali SR; Jewell SW; Havlat L; Bast MA; Thompson JR; Eastwood DC; Bartlett NL; Armitage JO; Wagner-Johnston ND; Vose JM; Fenske TS
    Cancer; 2014 Jul; 120(14):2122-9. PubMed ID: 24711253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
    Melani C; Wilson WH; Roschewski M
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma.
    Nabhan C; Smith SM; Cifu AS
    JAMA; 2016 May; 315(19):2115-6. PubMed ID: 27187305
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: Inappropriate surveillance or necessary care?
    Hahn EE; Tang T; Lee JS; Munoz-Plaza CE; Shen E; Rowley B; Maeda JL; Mosen DM; Ruckdeschel JC; Gould MK
    Cancer; 2016 Mar; 122(6):908-16. PubMed ID: 26650715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.
    Dann EJ; Berkahn L; Mashiach T; Frumer M; Agur A; McDiarmid B; Bar-Shalom R; Paltiel O; Goldschmidt N
    Br J Haematol; 2014 Mar; 164(5):694-700. PubMed ID: 24313286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
    Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern of Imaging after Lung Cancer Resection. 1992-2005.
    Sharma G; Nishi SP; Lin YL; Kuo YF; Goodwin JS; Riall TS
    Ann Am Thorac Soc; 2016 Sep; 13(9):1559-67. PubMed ID: 27243464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry.
    Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Ekwattanakit S; Khuhapinant A; Norasetthada L; Nawarawong W; Makruasi N; Kanitsap N; Sirijerachai C; Chansung K; Wong P; Numbenjapon T; Prayongratana K; Suwanban T; Wongkhantee S; Praditsuktavorn P; Intragumtornchai T;
    Ann Hematol; 2017 Jan; 96(1):57-64. PubMed ID: 27752821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of follow-up endoscopic examination in treatment response assessment for patients with gastric diffuse large B cell lymphoma.
    Yoon SB; Lee IS; Lee HN; Kim E; Kim W; Lee HH; Lee BI; Choi MG; Jung SE; Choi BO; Park GS; Cho SG
    Scand J Gastroenterol; 2016 Sep; 51(9):1111-7. PubMed ID: 27175513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.